Epimedokoreanin B blocks autophagic flux to inhibit progression of triple negative breast cancer through targeting MCOLN1/TRPML1 channel.

Results establish EKB as a promising therapeutic candidate that couples autophagy blockade with immune activation, and highlight oxidative stress as a significant contributing mechanism underlying its anticancer effects.